Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering

Core Points - Benitec Biopharma Inc. has announced the pricing of its underwritten public offering of 5,930,000 shares and a concurrent registered direct offering of 1,481,481 shares at an offering price of $13.50 per share [1] - The total gross proceeds from both offerings are expected to be approximately $100 million, which will be used for product candidate development, working capital, and general corporate purposes [2] Offering Details - The underwriters have a 30-day option to purchase up to an additional 889,500 shares on the same terms [1] - Leerink Partners, TD Cowen, and Evercore ISI are acting as bookrunning managers and placement agents for the offerings [3] Regulatory Information - The SEC declared effective a registration statement on Form S-3 for these securities on September 29, 2025 [4]